Advertisement

Topics

Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via Transradial Approach

2015-03-17 02:54:20 | BioPortfolio

Published on BioPortfolio: 2015-03-17T02:54:20-0400

Clinical Trials [2940 Associated Clinical Trials listed on BioPortfolio]

Patient Comfort With Vascular Closure

The purpose of this research study is to collect information on the amount of discomfort patients experience with one of two different vascular blood vessel closure devices, the MynxM5 Vas...

Optimized Heparin Regimen in Vascular Surgery

Hypothesis: Optimal anticoagulation defined as an Activated Clotting Time (ACT) of 300 to 350 seconds obtained by weight-adjusted doses of unfractionated heparin (UFH) will improve the hem...

Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis

The HDH device is intended for creating sutureless vascular anastomosis in various blood vessels. The HDH device consists of four parts: an elastic tube (graft), docking head (anastomotic ...

A Feasibility Study Evaluating the Use of SafeBreak Vascular in the Geriatric Trauma Population

SafeBreak Vascular is a medical device indicated for fluid flow control during the administration of IV fluids/medication to the patient's vascular system and to aid in the prevention of u...

HeRO Vascular Access Device Bacteremia Study

The purpose of this study is to compare the safety and effectiveness of the HeRO Vascular Access Device in access challenged (e.g., catheter-dependent) hemodialysis patients. It is hypothe...

PubMed Articles [17663 Associated PubMed Articles listed on BioPortfolio]

Anticoagulation Obtained Below the Arterial Clamp Using a Single Fixed Bolus of Heparin in Vascular Surgery: A Pilot Study.

No clear recommendations exist regarding the optimal dosing of unfractionated heparin (UFH) during vascular surgery. Moreover, little is known about the effect of the UFH bolus downstream of the arter...

Vascular Anomalies (Part II): Interventional Therapy of Peripheral Vascular Malformations.

 The International Society for the Study of Vascular Anomalies (ISSVA) categorizes vascular anomalies into vascular tumors and vascular malformations. Vascular malformations are further divided into...

The role of adventitia in hypoxic vascular remodeling.

As an important site for the production, storage and release of key regulators for vascular function, the vascular adventitia is thought to be a damage sensing tissue in the vascular wall under certai...

Recent trends in Publications of US and European Directors in Vascular Surgery.

We hypothesized that there may be significant differences between academic productivity of the vascular training programs in the United States (US) and Europe. In an effort to explore theory, we revie...

Early Treatment at a Referral Center Improves Outcomes for Patients with Acute Vascular Disease.

Patients with acute vascular disease frequently need specialized management that may require transfer to a vascular referral center. While transfer may be medically necessary, it can delay definitive ...

Medical and Biotech [MESH] Definitions

The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.

Secondary headache disorders attributed to a variety of cranial or cervical vascular disorders, such as BRAIN ISCHEMIA; INTRACRANIAL HEMORRHAGES; and CENTRAL NERVOUS SYSTEM VASCULAR MALFORMATIONS.

A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR C in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.

A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR D in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.

The active alterations of vascular wall structures, often leading to elevated VASCULAR RESISTANCE. It is associated with AGING; ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERTENSION; PREGNANCY; PULMONARY HYPERTENSION; and STROKE, but is also a normal part of EMBRYOGENESIS.

More From BioPortfolio on "Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via Transradial Approach"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial